



PATENT APPLICATION
DOCKET NO.: 00537/168002
Patent Ref. No. 00537/168002

RECEIVED
MAR 18 2003
TECH CENTER 1600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Katy Drieu

Application No.: 09/879,306

Group Art Unit: 1614

Filed: June 12, 2001

Examiner: JARVIS, WILLIAM R A

Title: GINKGOLIDES FOR INHIBITION OF MEMBRANE EXPRESSION OF BENZODIAZEPINE RECEPTORS

CERTIFICATE OF MAILING

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Date of Deposit:

3-11-2003
Alan F. Feeney
Alan F. Feeney

1st SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b)(4), or
(Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits; whichever occurs last)

☐ under 37 CFR 1.97(c) together with either:

☐ a Statement under 37 CFR 1.97(e), as checked below, or

☐ a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:

☐ a Statement under 37 CFR 1.97(e), as checked below, and

☐ a Petition under 37 CFR 1.97(d)(2), and

☐ a \$130.00 petition fee set forth in 37 CFR 1.17(i).

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

☐ Applicant requests that the attached IDS and cited reference(s) [] be placed in the application filewrapper.
(Filed after payment of issue fee)

☒ Some of the listed references were cited in Search Reports in counter part European and Hungarian applications.

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449 with references noted thereon.
- ☒ Copies of some of the reference(s) noted on the enclosed form 1449 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. 08/575,902, Filed December 20, 1995, from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)).

Concise Explanation Requirement (non-English references):

- ☒ The "concise explanation" requirement for reference(s): HU P9601295 A, under 37 CFR 1.98(a)(3), is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☒ the enclosed U.S. Patent No. 5,541,183 issued July 30, 1996.

It is requested that the information disclosed herein be made of record in this application, and that the references listed on the enclosed form PTO-1449 appear under the "References Cited" heading of any Patent which issues from this application, (MPEP 1302.12).

Method of payment:


- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.
- ☐ Applicant(s) hereby authorize the Assistant Commissioner to charge any additional fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.
- ☒ No fees are believed to be due for this submission. However, the Assistant Commissioner is hereby authorized to charge any fees that may be deemed to be due and/or credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.

Respectfully submitted,

BIOMEASURE, INCORPORATED

Dated: 3-11-2003

By


Alan F. Feeney, Attorney for Applicant(s)
Registration No.: 43,609

27 Maple Street
Milford, Massachusetts 01757
Telephone: (508) 478-0144
Facsimile: (508) 473-3531

ATTORNEY DOCKET NO.
00537/168002APPLICATION NO.
09/879,306INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

APPLICANT
Katy DrieuFILING DATE
June 12, 2001GROUP
1614

U.S. PATENT DOCUMENTS

INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	BA	5,541,183	7/30/96	Park et al.			
	BB	4,734,280	3/29/88	Braquet			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	Blasquez, C. et al., "Effect of Platelet-Activating Factor on Hypothalamic and Hypophyseal Pro-Opiomelanocortin-related Peptides and Hypothalamo-Pituitary-Adrenal Axis in the Rat", European Journal of Pharmacology, 177:145-153 (1990).
BD	Boralle, N. et al., "Ginkgo Biloba: A Review of its Chemical Composition", Ginkgolides-Chemistry, Biology, Pharmacology and Clinical Perspectives, Edited by P. Braquet, Ph.D., D.Sc., J.R. Prous Science Publishers, S.A., Les Plessis Robinson, France, 1:9-25 (1988).
BE	Krieglstein, J., "Neuroprotective Properties of Ginkgo Biloba - Constituents", Z. Phytother, 15(2):92-96 (1994).

EXAMINER

DATE CONSIDERED

